July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything ab...

The ASCO Post

July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything ab...

The ASCO Post

July 09, 2026

Top 10 Evidence-Based Essentials in Otolaryngology

A structured framework of evidence-based guidelines and landmark clinical trials used in clinical practice

Conexiant

July 07, 2026

Medical Oddities: When a Brush Beats a Scalpel

This research roundup has brain drama, bleeding control, skin science, and tiny brushes.

Conexiant

June 30, 2026

Top 10 Growing Metro Areas With Active HPSAs

These 10 metropolitan areas reported population gains and active federal shortage area designations identified in census and health care workforce data.

Conexiant

June 24, 2026

Promising early results for a new treatment in head and neck cancer

Victoria Villaflor, MD shared promising early results at ASCO 2026 for a new treatment approach in head and neck cancer.

UCI Health

June 22, 2026

Accuracy of AI Laryngeal Disorder Detection

Review of 88 studies found AI systems achieved high accuracy for identifying abnormal voices, but performance declined among higher-level laryngeal disorder classifications.

Conexiant

June 22, 2026

Deprivation Tied to Lower HNC-Specific QOL

The differences were present before patients began any treatment, suggesting quality-of-life gaps may be established before therapy begins.

Conexiant

June 19, 2026

Most Miss Streamlined Neck Mass Dx Path

Same-visit biopsy and fewer empiric workup steps were linked to faster pathologic diagnosis in a retrospective analysis.

Conexiant

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant